Investigational Agents for the Treatment of Resistant Yeasts and Molds

[1]  N. Wiederhold.  Review of the Novel Investigational Antifungal Olorofim , 2020, Journal of fungi.

[2]  J. Buer,et al.  In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus. , 2020, International journal of antimicrobial agents.

[3]  A. Chowdhary,et al.  Manogepix (APX001A) In Vitro Activity against Candida auris: Head-to-Head Comparison of EUCAST and CLSI MICs , 2020, Antimicrobial Agents and Chemotherapy.

[4]  A. Bonifaz,et al.  Endemic mycoses: epidemiology and diagnostic strategies , 2020, Expert review of anti-infective therapy.

[5]  M. Arendrup,et al.  In Vitro Activity of Manogepix (APX001A) and Comparators against Contemporary Molds: MEC Comparison and Preliminary Experience with Colorimetric MIC Determination , 2020, Antimicrobial Agents and Chemotherapy.

[6]  S. Strasser,et al.  Epidemiology and risk factors for invasive fungal disease in liver transplant recipients in a tertiary transplant center , 2020, Transplant infectious disease : an official journal of the Transplantation Society.

[7]  Matthias Misslinger,et al.  Structural basis of HapEP88L-linked antifungal triazole resistance in Aspergillus fumigatus , 2020, Life Science Alliance.

[8]  C. Lass‐Flörl,et al.  Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached? , 2020, Journal of fungi.

[9]  B. Elewski,et al.  A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail. , 2020 .

[10]  J. Buer,et al.  Antibiofilm activity of antifungal drugs, including the novel drug olorofim, against Lomentospora prolificans. , 2020, The Journal of antimicrobial chemotherapy.

[11]  M. Arendrup,et al.  Manogepix (APX001A) Displays Potent In Vitro Activity against Human Pathogenic Yeast, but with an Unexpected Correlation to Fluconazole MICs , 2020, Antimicrobial Agents and Chemotherapy.

[12]  S. Filler,et al.  Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus , 2020, Antimicrobial Agents and Chemotherapy.

[13]  G. Thompson,et al.  Aspiring Antifungals: Review of Current Antifungal Pipeline Developments , 2020, Journal of fungi.

[14]  K. Borroto-Esoda,et al.  Pan-resistant Candida auris Isolates from the Outbreak in New York are Susceptible to Ibrexafungerp: A Glucan Synthase Inhibitor. , 2020, International journal of antimicrobial agents.

[15]  M. Castanheira,et al.  Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018) , 2020, Antimicrobial Agents and Chemotherapy.

[16]  A. Chowdhary,et al.  Rezafungin In Vitro Activity against Contemporary Nordic Clinical Candida Isolates and Candida auris Determined by the EUCAST Reference Method , 2020, Antimicrobial Agents and Chemotherapy.

[17]  M. Davis,et al.  Ibrexafungerp: A novel oral glucan synthase inhibitor. , 2020, Medical mycology.

[18]  G. Catano,et al.  The Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity against Candida auris , 2019, Antimicrobial Agents and Chemotherapy.

[19]  Yiyou Gu,et al.  Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis , 2019, Antimicrobial Agents and Chemotherapy.

[20]  J. Meis,et al.  Multiresistant Fusarium Pathogens on Plants and Humans: Solutions in (from) the Antifungal Pipeline? , 2019, Infection and drug resistance.

[21]  M. Kapoor,et al.  Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species , 2019, Antimicrobial Agents and Chemotherapy.

[22]  C. Clancy,et al.  738. Potent In Vitro activity of Rezafungin (RZF) Against Aspergillus Clinical Isolates Recovered From Lung Transplant Patients Who Have Received ≥3 Months of Triazole Prophylaxis , 2019, Open Forum Infectious Diseases.

[23]  G. Catano,et al.  1954. In vivo Efficacy of Delayed Therapy with the Novel Inositol Acyltransferase Inhibitor Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis , 2019, Open Forum Infectious Diseases.

[24]  W. Powderly,et al.  MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. , 2019, The Journal of antimicrobial chemotherapy.

[25]  A. Borman,et al.  In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae , 2019, The Journal of antimicrobial chemotherapy.

[26]  E. Berkow,et al.  In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations , 2019, Antimicrobial Agents and Chemotherapy.

[27]  E. Dannaoui,et al.  Antifungal combinations in Mucorales: A microbiological perspective , 2019, Mycoses.

[28]  B. Wickes,et al.  Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus , 2019, Antimicrobial Agents and Chemotherapy.

[29]  E. Garvey,et al.  Impact of the Major Candida glabrata Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161 , 2019, Antimicrobial Agents and Chemotherapy.

[30]  Kazuhiro Ito,et al.  In vitro antifungal activity of a novel topical triazole PC945 against emerging yeast Candida auris , 2019, The Journal of antimicrobial chemotherapy.

[31]  Kazuhiro Ito,et al.  Antifungal synergy of a topical triazole, PC945, with a systemic triazole against respiratory Aspergillus fumigatus infection , 2019, Scientific Reports.

[32]  K. Yanagihara,et al.  The Novel Arylamidine T-2307 Selectively Disrupts Yeast Mitochondrial Function by Inhibiting Respiratory Chain Complexes , 2019, Antimicrobial Agents and Chemotherapy.

[33]  A. Casadevall,et al.  On the emergence of Candida auris: climate change, azoles, swamps and birds , 2019, bioRxiv.

[34]  M. Cuenca‐Estrella,et al.  In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies. , 2019, The Journal of antimicrobial chemotherapy.

[35]  J. Qiu,et al.  Efficacy of Oral Encochleated Amphotericin B in a Mouse Model of Cryptococcal Meningoencephalitis , 2019, mBio.

[36]  R. Sobel,et al.  Ibrexafungerp, a Novel Oral Antifungal, Demonstrates No Reproductive or Developmental Harm in Preclinical Models [25J] , 2019, Obstetrics & Gynecology.

[37]  M. Kaku,et al.  Efficacy of T-2307, a novel arylamidine, against ocular complications of disseminated candidiasis in mice , 2019, The Journal of antimicrobial chemotherapy.

[38]  M. Cuenca‐Estrella,et al.  In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies , 2019, The Journal of antimicrobial chemotherapy.

[39]  S. Kelly,et al.  In Vitro Activities of the Novel Investigational Tetrazoles VT-1161 and VT-1598 Compared to the Triazole Antifungals against Azole-Resistant Strains and Clinical Isolates of Candida albicans , 2019, Antimicrobial Agents and Chemotherapy.

[40]  S. Seyedmousavi,et al.  Efficacy of Olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in Murine Models of Profound Neutropenia and Chronic Granulomatous Disease , 2019, Antimicrobial Agents and Chemotherapy.

[41]  M. Cushion,et al.  Rezafungin Prophylactic Efficacy in a Mouse Model of Pneumocystis Pneumonia , 2019, Biology of Blood and Marrow Transplantation.

[42]  Brendan R. Jackson,et al.  Estimation of Direct Healthcare Costs of Fungal Diseases in the United States. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  Brendan R. Jackson,et al.  Candida auris: The recent emergence of a multidrug-resistant fungal pathogen. , 2018, Medical mycology.

[44]  E. Garvey,et al.  The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates In Vitro and In Vivo Activity against Candida auris , 2018, Antimicrobial Agents and Chemotherapy.

[45]  Á. Soriano,et al.  1718. Rezafungin Clinical Safety and Efficacy in Patients With Candidemia and/or Invasive Candidiasis in the Randomized, Double-Blind, Multicenter, Phase 2 STRIVE Study , 2018, Open Forum Infectious Diseases.

[46]  C. Lambros,et al.  1413. A Phase IIa Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of Encochleated Amphotericin B in Patients with Mucocutaneous (Esophogeal, Oropharyngeal, Vulvovaginal) Candidiasis Who are Refractory or Intolerant to Standard Non-Intravenous Therapies , 2018, Open Forum Infectious Diseases.

[47]  V. Haley,et al.  Candida auris in Healthcare Facilities, New York, USA, 2013–2017 , 2018, Emerging infectious diseases.

[48]  Jeffrey B Locke,et al.  Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species , 2018, The Journal of antimicrobial chemotherapy.

[49]  E. Garvey,et al.  The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis , 2018, Antimicrobial Agents and Chemotherapy.

[50]  E. Garvey,et al.  The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis , 2018, The Journal of antimicrobial chemotherapy.

[51]  J. Rex,et al.  The Orotomide Olorofim Is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis , 2018, Antimicrobial Agents and Chemotherapy.

[52]  S. Wring,et al.  Lack of Impact by SCY‐078, a First‐in‐Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug‐Drug Interactions , 2018, Journal of clinical pharmacology.

[53]  M. Ghannoum,et al.  Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model , 2018, The Journal of antimicrobial chemotherapy.

[54]  S. Ranque,et al.  Scedosporium and Lomentospora: an updated overview of underrated opportunists. , 2018, Medical mycology.

[55]  E. Garvey,et al.  The Novel Fungal Cyp51 Inhibitor VT-1598 Is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by Coccidioides posadasii and Coccidioides immitis , 2018, Antimicrobial Agents and Chemotherapy.

[56]  E. Garvey,et al.  Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus , 2018, The Journal of antimicrobial chemotherapy.

[57]  M. Ghannoum,et al.  In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris , 2018, Antimicrobial Agents and Chemotherapy.

[58]  Brendan R. Jackson,et al.  Recognition of Azole-Resistant Aspergillosis by Physicians Specializing in Infectious Diseases, United States , 2018, Emerging infectious diseases.

[59]  R. Kolamunnage-Dona,et al.  Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus , 2017, The Journal of infectious diseases.

[60]  J. Perfect,et al.  Tolerability profile of the current antifungal armoury , 2018, The Journal of antimicrobial chemotherapy.

[61]  D. Perlin,et al.  Fungal infections 5 The global problem of antifungal resistance: prevalence, mechanisms, and management , 2017 .

[62]  K. Borroto-Esoda,et al.  SCY-078 Demonstrates Significant Tissue Penetration in Rats and Mice Following Oral or IV Administration , 2017, Open Forum Infectious Diseases.

[63]  R. Kolamunnage-Dona,et al.  Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease , 2017, mBio.

[64]  M. Hui,et al.  Effects of Echinocandins in Combination with Nikkomycin Z against Invasive Candida albicans Bloodstream Isolates and the fks Mutants , 2017, Antimicrobial Agents and Chemotherapy.

[65]  Maristela Pereira,et al.  Antifungal Resistance, Metabolic Routes as Drug Targets, and New Antifungal Agents: An Overview about Endemic Dimorphic Fungi , 2017, Mediators of inflammation.

[66]  M. Tashiro,et al.  In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen , 2017, The Journal of antimicrobial chemotherapy.

[67]  D. Kelly,et al.  The Tetrazole VT-1161 Is a Potent Inhibitor of Trichophyton rubrum through Its Inhibition of T. rubrum CYP51 , 2017, Antimicrobial Agents and Chemotherapy.

[68]  E. Garvey,et al.  Efficacy of the Investigational Antifungal VT-1161 in Treating Naturally Occurring Coccidioidomycosis in Dogs , 2017, Antimicrobial Agents and Chemotherapy.

[69]  D. Kelly,et al.  In Vitro and In Vivo Antifungal Profile of a Novel and Long-Acting Inhaled Azole, PC945, on Aspergillus fumigatus Infection , 2017, Antimicrobial Agents and Chemotherapy.

[70]  K. Borroto-Esoda,et al.  Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis , 2017, Antimicrobial Agents and Chemotherapy.

[71]  D. Boulware,et al.  Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs. , 2016, Medical mycology.

[72]  A. Vaidya,et al.  CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility , 2016, The Journal of Antibiotics.

[73]  E. Berkow,et al.  Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species , 2017, Frontiers in microbiology.

[74]  B. Alexander,et al.  Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds , 2016, Antimicrobial Agents and Chemotherapy.

[75]  Christina M. Henderson,et al.  VT-1129 and VT-1161 have in vitro activity against Candida isolates from patients with chronic mucocutaneous candidiasis , 2016 .

[76]  M. Slater,et al.  F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase , 2016, Proceedings of the National Academy of Sciences.

[77]  T. Chiller,et al.  The Global Burden of Fungal Diseases. , 2016, Infectious disease clinics of North America.

[78]  T. Patterson,et al.  The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata. , 2016, The Journal of antimicrobial chemotherapy.

[79]  E. Garvey,et al.  The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii , 2016, Antimicrobial Agents and Chemotherapy.

[80]  E. Garvey,et al.  VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection , 2015, Antimicrobial Agents and Chemotherapy.

[81]  J. Sobel,et al.  Efficacy of the Clinical Agent VT-1161 against Fluconazole-Sensitive and -Resistant Candida albicans in a Murine Model of Vaginal Candidiasis , 2015, Antimicrobial Agents and Chemotherapy.

[82]  M. Castanheira,et al.  In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species. , 2015, Diagnostic microbiology and infectious disease.

[83]  D. Kelly,et al.  The Clinical Candidate VT-1161 Is a Highly Potent Inhibitor of Candida albicans CYP51 but Fails To Bind the Human Enzyme , 2014, Antimicrobial Agents and Chemotherapy.

[84]  J. Galgiani,et al.  Efficacy of Nikkomycin Z for respiratory coccidioidomycosis in naturally infected dogs. , 2013, Medical mycology.

[85]  D. Vugia,et al.  Increase in Reported Coccidioidomycosis — United States, 1998–2011 , 2013, MMWR. Morbidity and mortality weekly report.

[86]  Ronald N. Jones,et al.  Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against Fusarium and Scedosporium Species Identified Using Molecular Methods , 2011, Antimicrobial Agents and Chemotherapy.

[87]  T. Horii,et al.  In Vitro Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds , 2011, Antimicrobial Agents and Chemotherapy.

[88]  M. Cushion,et al.  Susceptibility of Pneumocystis to Echinocandins in Suspension and Biofilm Cultures , 2011, Antimicrobial Agents and Chemotherapy.

[89]  W. Melchers,et al.  Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? , 2009, The Lancet. Infectious diseases.

[90]  M. Pfaller,et al.  Activity of MGCD290, a Hos2 Histone Deacetylase Inhibitor, in Combination with Azole Antifungals against Opportunistic Fungal Pathogens , 2009, Journal of Clinical Microbiology.

[91]  J. Galgiani,et al.  Pharmacokinetics of Nikkomycin Z after Single Rising Oral Doses , 2009, Antimicrobial Agents and Chemotherapy.

[92]  A. Kimura,et al.  In Vitro and In Vivo Antifungal Activities of T-2307, a Novel Arylamidine , 2008, Antimicrobial Agents and Chemotherapy.

[93]  L. Zarif,et al.  Efficacy of Orally Delivered Cochleates Containing Amphotericin B in a Murine Model of Aspergillosis , 2002, Antimicrobial Agents and Chemotherapy.

[94]  B. Zimmer,et al.  Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis , 1990, Antimicrobial Agents and Chemotherapy.